CA2237023C - Formulation amelioree pour l'administration de composes steroidiens - Google Patents

Formulation amelioree pour l'administration de composes steroidiens Download PDF

Info

Publication number
CA2237023C
CA2237023C CA002237023A CA2237023A CA2237023C CA 2237023 C CA2237023 C CA 2237023C CA 002237023 A CA002237023 A CA 002237023A CA 2237023 A CA2237023 A CA 2237023A CA 2237023 C CA2237023 C CA 2237023C
Authority
CA
Canada
Prior art keywords
cyclodextrin
steroids
dhea
steroid
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002237023A
Other languages
English (en)
Other versions
CA2237023A1 (fr
Inventor
Joseph Rubinfeld
Julius A. Vida
H. Leon Bradlow
Elliott L. Fineman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astex Pharmaceuticals Inc
Original Assignee
Supergen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/744,979 external-priority patent/US5824668A/en
Application filed by Supergen Inc filed Critical Supergen Inc
Publication of CA2237023A1 publication Critical patent/CA2237023A1/fr
Application granted granted Critical
Publication of CA2237023C publication Critical patent/CA2237023C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Nanotechnology (AREA)
  • Obesity (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Medical Informatics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention concerne des formulations cyclodextriniques pour l'administration de 5 beta stéroïdes dont alpha étiocholonolone, beta étiocholonolone et étiocholandione. Elle porte également sur des formulations cyclodextriniques comprenant au moins un des 5 beta stéroïdes et de la déshydroépiandostérone (DHEA). Lesdites formulations conviennent à l'administration parentérale, en particulier l'administration par voie intraveineuse et également au traitement d'un état qui répond au traitement aux 5 beta stéroïdes seuls ou conjointement avec DHEA, en particulier lorsque l'on désire réduire la quantité de DHEA administrée. Ces états comprennent l'obésité, le syndrome diabétique, l'hypercorticoïdisme associé au diabète ou leur combinaison, des troubles anémiques dont, entre autres, l'anémie aplasique et la neutropénie ou l'anémie associée à une insuffisance rénale ou induite par une chimiothérapie ou les rayons, les troubles autoimmuns ou inflammatoires tels que le lupus érythémateux.
CA002237023A 1995-11-13 1996-11-12 Formulation amelioree pour l'administration de composes steroidiens Expired - Fee Related CA2237023C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US655795P 1995-11-13 1995-11-13
US60/006,557 1995-11-13
US08/744,979 1996-11-07
US08/744,979 US5824668A (en) 1996-11-07 1996-11-07 Formulation for administration of steroid compounds
PCT/US1996/018189 WO1997017992A1 (fr) 1995-11-13 1996-11-12 Formulation amelioree pour l'administration de composes steroidiens

Publications (2)

Publication Number Publication Date
CA2237023A1 CA2237023A1 (fr) 1997-05-22
CA2237023C true CA2237023C (fr) 2008-02-19

Family

ID=26675782

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002237023A Expired - Fee Related CA2237023C (fr) 1995-11-13 1996-11-12 Formulation amelioree pour l'administration de composes steroidiens

Country Status (7)

Country Link
EP (1) EP0866722A1 (fr)
JP (1) JP2002507960A (fr)
CN (1) CN1201397A (fr)
AU (1) AU718232B2 (fr)
CA (1) CA2237023C (fr)
IL (1) IL124001A (fr)
WO (1) WO1997017992A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1304190B1 (it) * 1998-12-18 2001-03-08 Euphar Group Srl Clatrati di deidroepiandrosterone e relative composizionifarmaceutiche
EP1223941B1 (fr) * 1999-10-25 2008-11-05 Hollis-Eden Pharmaceuticals Inc. Traitements therapeutiques pour des deficiences en cellules sanguines par des steroides
FR2847475B1 (fr) * 2002-11-25 2006-06-23 Oreal COMPOSITION COSMETIQUE OU PHARMACEUTIQUE ASSOCIANT UN AGENT MODULATEUR DE L'EXPRESSION DE L'OXYSTEROL 7alpha-HYDROXYLASE ET UN SUBSTRAT BIOLOGIQUE DE LADITE ENZYME
CN101961311B (zh) * 2010-09-21 2012-11-21 中山大学 一种5α-雄甾(烷)-3β,5,6β-三醇注射剂及其制备方法
CN103330946B (zh) * 2013-05-29 2015-03-25 广州市赛普特医药科技有限公司 5α-雄甾-3β,5,6β-三醇注射剂其制备方法
CN105078954A (zh) * 2015-08-20 2015-11-25 南京华宽信息咨询中心 一种治疗急性肾衰药物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666898A (en) * 1983-12-28 1987-05-19 Jackson Lab. Treatment of obesity, diabetes and other symptoms of hypercorticoidism using etiocholanolones
US4507289A (en) * 1983-12-28 1985-03-26 Progenics, Inc. Treatment of diabetes and other symptoms of hypercorticoidism using a synergistic combination of etiocholanolones and estrogen
EP0261891A3 (fr) * 1986-09-22 1990-09-05 Progenics, Inc. Compositions pharmaceutiques contenant de l'étiochiolandione
US5120720A (en) * 1990-09-20 1992-06-09 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Preparation of lipophile:hydroxypropylcyclodextrin complexes by a method using co-solubilizers
FR2667070A1 (fr) * 1990-09-21 1992-03-27 Besins Iscovesco Labo Sterouides inclus dans des cyclodextrines procede pour leur preparation complexes et formes goleniques correspondants et leurs applications therapeutiques.

Also Published As

Publication number Publication date
AU718232B2 (en) 2000-04-13
WO1997017992A1 (fr) 1997-05-22
CA2237023A1 (fr) 1997-05-22
JP2002507960A (ja) 2002-03-12
EP0866722A1 (fr) 1998-09-30
CN1201397A (zh) 1998-12-09
IL124001A (en) 2004-07-25
AU1158797A (en) 1997-06-05

Similar Documents

Publication Publication Date Title
US5824668A (en) Formulation for administration of steroid compounds
US6284747B1 (en) Pharmaceutical formulation
Conceicao et al. Cyclodextrins as drug carriers in pharmaceutical technology: the state of the art
US4877774A (en) Administration of steroid hormones
US5997856A (en) Method and compositions for solubilization and stabilization of polypeptides, especially proteins
Rajewski et al. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery
US4596795A (en) Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
EP1059942B1 (fr) Compositions pharmaceutiques contenant des cyclodextrines et des taxoides
Szejtli Cyclodextrin complexed generic drugs are generally not bio-equivalent with the reference products: therefore the increase in number of marketed drug/cyclodextrin formulations is so slow
EA034565B1 (ru) Композиции левосимендана для внутривенного введения в виде инфузии или инъекции и концентрата для инфузии
JP7526175B2 (ja) Ｂｃｌ－２阻害剤のシクロデキストリンに基づく製剤
Holbrook et al. Aqueous hydrocortisone mouthwash solution: clinical evaluation
CA2237023C (fr) Formulation amelioree pour l'administration de composes steroidiens
Uekama et al. Improvement of drug properties by cyclodextrins
WO2005011617A2 (fr) Formes posologiques a administrer par voie transmuqueuse pour systemes de liberation de produit chimique steroide dirige sur le cerveau
EP0399716B1 (fr) Composition hypoallergénique stéroide à activité anesthésiante/hypnotique
EA008776B1 (ru) Жидкая стабильная композиция оксазафосфорина с месной
US20040072797A1 (en) Storage stable eplerenone formulation
DE68906027T2 (de) Cyclodextrimpeptid-einschlusskomplexe.
Brewster et al. Intravenous and Buccal 2-Hydroxypropyl-β-Cyclodextrin Formulations of E2-CDS—Phase I Clinical Trials
US20040014695A1 (en) Pharmaceutical formulation

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed